Adjunctive CB1 Agonist Nabilone in Inpatients With Active Suicidal Ideation

Phase 2 Withdrawn The University of Texas Health Science Center, Houston

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Suicide is a major crisis worldwide with rates projected to continue to increase. There is currently a dearth of novel pharmacologic treatment options for suicide available on the market. The endocannabinoid system has been recently shown to be associated with mood disorders including suicidality. The aim of the study is to determine whether treatment with Nabilone is capable of reducing suicidal ideation in adults after 3 days.

Timeline

Start: 2021-04
Primary completion: 2022-04
Completion: 2022-04

Outcome

Outcome not reported

Stopped: “The study was stopped due to drug unavailability. The drug is unavailable because production was discontinued in the US.”

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Nabilone	Other / unclassified	2 mg	Oral

Indications

No indication recorded.